|
||
|
| Home |  |
Firm Description | |
Sectors Covered | |
Completed Transactions | |
Testimonials | |
Principals | |
M&A Report and Publications |
|
Contact Us | |
| Acquiring Party | Ikaria Inc., a leader in gaseous drugs including inhaled nitric oxide for treatment of hypoxic respiratory failure in newborns. |
|---|---|
| Transferring Party | INO Therapeutics, a specialty pharmaceutical company. |
| Sector | Biopharmaceuticals |
| Date | February 22, 2007 |
| Analysis The Deal, valued at - $670m, will create a leadership position in therapeutic gases and critical care medicine. Financed by New Mountain Capital, ARCH Venture Partners, and Venrock Associates. INO Therapeutics is being acquired from The Linde Group, which will retain an equity position in the new entity. INO's sales are -$160m(4.18x). | |
The Walden Group is a leading healthcare investment banking firm specializing in mergers, acquisitions and strategic transactions. It also invests its own funds and, together with its expert operational partners, provides value-added services to help special companies reach critical milestones. This information is copyright © 2004-2007 The Walden Group, Inc. This information is provided as a service to the public but remains the intellectual property of The Walden Group, Inc and may not be reproduced in any manner without the written permission of The Walden Group, Inc. The information contained in the transactions table was derived from publicly available and other sources. Transaction analysis and other information are based, in part, upon public comments, Walden Group research and judgments, and reporting and research of others. The information is not intended to be relied upon as pronouncements by the transaction participants or for any other reason. | |